Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Advancing Treatment for Metastatic Triple-Negative Breast Cancer: Dr. Aditya Bardia’s Work in the ASCENT Trial

    On May 20, 2024, Dr. Aditya Bardia and his colleagues published the final results of the Phase III ASCENT trial, reinforcing Sacituzumab Govitecan (SG) as a superior treatment option over…

    2025.02.26
  • Annual Review | Dr. Ou Bai: Focusing on Advances and Challenges in PTCL Diagnosis and Treatment in 2024

    In recent years, the field of hematologic oncology has seen numerous encouraging breakthroughs, with Chinese scholars increasingly contributing to research in cell therapy, significantly advancing the development of both the discipline and clinical practice. Hematology Frontier specially invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the progress in the…

    2025.02.25
  • Dr. Zhanhong Chen: Exploring New Treatment Pathways for HR+ Advanced Breast Cancer – The Future Role of CDK4/6 Inhibitors and Novel Targeted Therapies

    In the evolving landscape of breast cancer treatment, the management of HR+ advanced breast cancer remains a central focus. During the Northern China Breast Cancer Salon – Annual Progress Review, Dr. Zhanhong Chen from Zhejiang Cancer Hospital delivered an in-depth analysis on the stratified treatment approach for HR+ advanced breast cancer. Following the meeting, Oncology…

    2025.02.25
  • ASCO GI 2025 | Dr. Zhenyu Lin: Short-Course Radiotherapy Plus Targeted, Immuno-, and Chemotherapy for High-Risk LA

    At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), the UNION TNT study, led by Dr. Tao Zhang and Dr. Kaixiong Tao from the Multidisciplinary…

    2025.02.25
  • European Hematology Association (EHA) Conference Highlights !

    The curtains have closed on another enlightening EHA Congress, a beacon of innovation in hematology. This year’s gathering was a testament to the relentless pursuit of medical advancement, with a…

    2025.02.25
  • ASCO GI 2025 | Dr. Zhiqiang Wang: Significant Advantages of Albumin-Bound Docetaxel in Second-Line Treatment for Advanced Gastric Cancer

    As one of the most important academic conferences in the field of gastrointestinal oncology, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) presents a wealth of early-phase drug development data, key registration studies, major research updates, and subgroup analyses every year. These findings represent the latest advancements in the diagnosis and treatment…

    2025.02.25
  • In-Depth Analysis丨Dr. Shu Liu & Dr. Li Ma: Choosing CDK4/6 Inhibitors for Adjuvant Intensified Treatment in HR+/HER2- Breast Cancer Patients

    Presenting Views and Analyzing Reasons Dr. Shu Liu: Choosing Abemaciclib For adjuvant intensified treatment in HR+/HER2- breast cancer patients, I prefer abemaciclib for the following reasons: First, the relevant study…

    2025.02.25
  • World’s First! Pioneering Pig-Human Liver and Kidney Xenotransplantation by Academician Dong Jiahong’s Team at Tsinghua Chang Gung Hospital

    This research successfully demonstrated the feasibility of using gene-edited pig organs in combined human organ transplantation, laying a crucial foundation for further studies and improvements in xenotransplantation technology. The gene-edited…

    2025.02.25
«previous next»
Recent Posts
  • Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
  • Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
  • Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top